Transcriptome analysis of adrenocortical cancers: From molecular classification to the identification of new treatments

Endocrine-Related Cancer

Volumn 18, Issue 2, 2011, Pages

  Ragazzon, Bruno ^a   Assié, Guillaume ^a,b   Bertherat, Jérôme ^a,b  

^a INSTITUT COCHIN   (France)

^b Inserm U1016 ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

BENZIMIDAZOLE; BETA CATENIN; PROTEIN P53; RETINOIC ACID; SOMATOMEDIN B; TRANSCRIPTOME; WNT PROTEIN;

ADRENAL CANCER; ADRENOCORTICAL CANCER; CANCER CLASSIFICATION; CELL CYCLE; DOWN REGULATION; DRUG ACTIVITY; GENE CLUSTER; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC DISORDER; HUMAN; MOLECULAR GENETICS; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; STEROIDOGENESIS; UPREGULATION;

ADRENAL CORTEX NEOPLASMS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS;

EID: 79953165342     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-10-0220     Document Type: Review

References (68)

1. Abiven G, Coste J, Groussin L, Anract P, Tissier F, Legmann P, Dousset B, Bertagna X & Bertherat J 2006 Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. Journal of Clinical Endocrinology and Metabolism 91 2650-2655. (doi:10.1210/jc.2005-2730)
2. Allolio B, Hahner S, Weismann D & Fassnacht M 2004 Management of adrenocortical carcinoma. Clinical Endocrinology 60 273-287. (doi:10.1046/j.1365-2265.2003.01881.x)
3. Assie G, Guillaud-Bataille M, Ragazzon B, Bertagna X, Bertherat J & Clauser E 2010 The pathophysiology, diagnosis and prognosis of adrenocortical tumors revisited by transcriptome analyses. Trends in Endocrinology and Metabolism 21 325-334. (doi:10.1016/j.tem.2009.12.009)
4. Boulle N, Logie A, Gicquel C, Perin L & Le Bouc Y 1998 Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism 83 1713-1720. (doi:10.1210/jc.83.5.1713)
5. Boulle N, Baudin E, Gicquel C, Logie A, Bertherat J, Penfornis A, Bertagna X, Luton JP, Schlumberger M & Le Bouc Y 2001 Evaluation of plasma insulin-like growth factor binding protein-2 as a marker for adrenocortical tumors. European Journal of Endocrinology 144 29-36. (doi:10.1530/eje.0.1440029)
6. Bourcigaux N, Gaston V, Logie A, Bertagna X, Le Bouc Y & Gicquel C 2000 High expression of cyclin E and G1 CDK and loss of function of p57KIP2 are involved in proliferation of malignant sporadic adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism 85 322-330. (doi:10.1210/jc.85.1.322)
7. Bourdeau I, Antonini SR, Lacroix A, Kirschner LS, Matyakhina L, Lorang D, Libutti SK & Stratakis CA 2004 Gene array analysis of macronodular adrenal hyperplasia confirms clinical heterogeneity and identifies several candidate genes as molecular mediators. Oncogene 23 1575-1585. (doi:10.1038/sj.onc. 1207277)
8. Caron de Fromentel C & Soussi T 1992 TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes, Chromosomes and Cancer 4 1-15. (doi:10.1002/gcc.2870040102)
9. Chen HY, Yu SL, Chen CH, Chang GC, Chen CY, Yuan A, Cheng CL, Wang CH, Terng HJ, Kao SF et al. 2007 A five-gene signature and clinical outcome in non-small-cell lung cancer. New England Journal of Medicine 356 11-20. (doi:10.1056/NEJMoa060096)
10. Chiang JM, Chou YH, Chen TC, Ng KF & Lin JL 2002 Nuclear β-catenin expression is closely related to ulcerative growth of colorectal carcinoma. British Journal of Cancer 86 1124-1129. (doi:10.1038/sj.bjc.6600214)
11. Clements WM, Wang J, Sarnaik A, Kim OJ, MacDonald J, Fenoglio-Preiser C, Groden J & Lowy AM 2002 β-Catenin mutation is a frequent cause of Wnt pathway activation in gastric cancer. Cancer Research 62 3503-3506. (Pubitemid 34651399)
12. DiGiammarino EL, Lee AS, Cadwell C, Zhang W, Bothner B, Ribeiro RC, Zambetti G & Kriwacki RW 2002 A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer. Nature Structural Biology 9 12-16. (doi:10.1038/nsb730)
13. Doghman M, Cazareth J & Lalli E 2008 The T cell factor/β-catenin antagonist PKF115-584 inhibits proliferation of adrenocortical carcinoma cells. Journal of Clinical Endocrinology and Metabolism 93 3222-3225. (doi:10.1210/jc.2008-0247)
14. Fassnacht M & Allolio B 2009 Clinical management of adrenocortical carcinoma. Best Practice and Research. Clinical Endocrinology and Metabolism 23 273-289. (doi:10.1016/j.beem.2008.10.008)
15. Fassnacht M, Beuschlein F, Vay S, Mora P, Allolio B & Reincke M 1998 Aminoglutethimide suppresses adrenocorticotropin receptor expression in the NCI-h295 adrenocortical tumor cell line. Journal of Endocrinology 159 35-42. (doi:10.1677/joe.0.1590035)
16. Fernandez-Ranvier GG, Weng J, Yeh RF, Khanafshar E, Suh I, Barker C, Duh QY, Clark OH & Kebebew E 2008a Identification of biomarkers of adrenocortical carcinoma using genomewide gene expression profiling. Archives of Surgery 143 841-846 (discussion 846). (doi:10.1001/archsurg.143.9.841)
17. Fernandez-Ranvier GG, Weng J, Yeh RF, Shibru D, Khafnashar E, Chung KW, Hwang J, Duh QY, Clark OH & Kebebew E 2008b Candidate diagnostic markers and tumor suppressor genes for adrenocortical carcinoma by expression profile of genes on chromosome 11q13. World Journal of Surgery 32 873-881. (doi:10.1007/s00268-008-9521-0)
18. Ferruzzi P, Ceni E, Tarocchi M, Grappone C, Milani S, Galli A, Fiorelli G, Serio M & Mannelli M 2005 Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R. Journal of Clinical Endocrinology and Metabolism 90 1332-1339. (doi:10.1210/jc.2004-0978)
19. de Fraipont F, El Atifi M, Cherradi N, Le Moigne G, Defaye G, Houlgatte R, Bertherat J, Bertagna X, Plouin PF, Baudin E et al. 2005 Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic acid microarrays identifies several candidate genes as markers of malignancy. Journal of Clinical Endocrinology and Metabolism 90 1819-1829. (doi:10.1210/jc.2004-1075)
20. Gaujoux S, Pinson S, Gimenez-Roqueplo AP, Amar L, Ragazzon B, Launay P, Meatchi T, Libe R, Bertagna X, Audebourg A et al. 2010 Inactivation of the APC gene is constant in adrenocortical tumors from patients with familial adenomatous polyposis but not frequent in sporadic adrenocortical cancers. Clinical Cancer Research 16 5133-5141. (doi:10.1158/1078-0432.CCR-10-1497)
21. Gaujoux S, Grabar S, Fassnacht M, Ragazzon B, Launay P, Libe R, Chokri I, Audebourg A, Royer B, Sbiera S et al. 2011 β-Catenin activation is associated with specific clinical and pathological characteristics and a poor outcome in adrenocortical carcinoma. Clinical Cancer Research 17 337-345. (doi:10.1158/1078-0432.CCR-10-2006)
22. Gicquel C, Bertagna X, Schneid H, Francillard-Leblond M, Luton JP, Girard F & Le Bouc Y 1994 Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism 78 1444-1453. (doi:10.1210/jc.78.6.1444)
23. Gicquel C, Raffin-Sanson ML, Gaston V, Bertagna X, Plouin PF, Schlumberger M, Louvel A, Luton JP & Le Bouc Y 1997 Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors. Journal of Clinical Endocrinology and Metabolism 82 2559-2565. (doi:10.1210/jc.82.8.2559)
24. Gicquel C, Bertagna X, Gaston V, Coste J, Louvel A, Baudin E, Bertherat J, Chapuis Y, Duclos JM, Schlumberger M et al. 2001 Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Research 61 6762-6767. (Pubitemid 32896498)
25. Giles RH, van Es JH & Clevers H 2003 Caught up in a Wnt storm: Wnt signaling in cancer. Biochimica et Biophysica Acta 1653 1-24. (doi:10.1016/S0304-419X(03)00005-2)
26. Giordano TJ, Thomas DG, Kuick R, Lizyness M, Misek DE, Smith AL, Sanders D, Aljundi RT, Gauger PG, Thompson NW et al. 2003 Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. American Journal of Pathology 162 521-531. (doi:10.1016/S0002-9440(10)63846-1)
27. Giordano TJ, Kuick R, Else T, Gauger PG, Vinco M, Bauersfeld J, Sanders D, Thomas DG, Doherty G & Hammer G 2009 Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clinical Cancer Research 15 668-676. (doi:10.1158/1078-0432.CCR-08-1067)
28. Grumbach MM, Biller BM, Braunstein GD, Campbell KK, Carney JA, Godley PA, Harris EL, Lee JK, Oertel YC, Posner MC et al. 2003 Management of the clinically inapparent adrenal mass ("incidentaloma"). Annals of Internal Medicine 138 424-429. (Pubitemid 36262654)
29. Henry I, Jeanpierre M, Couillin P, Barichard F, Serre JL, Journel H, Lamouroux A, Turleau C, de Grouchy J & Junien C 1989 Molecular definition of the 11p15.5 region involved in Beckwith-Wiedemann syndrome and probably in predisposition to adrenocortical carcinoma. Human Genetics 81 273-277. (doi:10.1007/BF00279003)
30. Hisada M, Garber JE, Fung CY, Fraumeni JF Jr & Li FP 1998 Multiple primary cancers in families with Li-Fraumeni syndrome. Journal of the National Cancer Institute 90 606-611. (doi:10.1093/jnci/90.8.606)
31. Hollstein M, Sidransky D, Vogelstein B & Harris CC 1991 p53 mutations in human cancers. Science 253 49-53. (doi:10.1126/science.1905840)
32. Ilvesmaki V, Kahri AI, Miettinen PJ & Voutilainen R 1993 Insulin-like growth factors (IGFs) and their receptors in adrenal tumors: high IGF-II expression in functional adrenocortical carcinomas. Journal of Clinical Endocrinology and Metabolism 77 852-858. (doi:10.1210/jc.77.3.852)
33. Kikuchi A 2003 Tumor formation by genetic mutations in the components of the Wnt signaling pathway. Cancer Science 94 225-229. (doi:10.1111/j.1349-7006. 2003.tb01424.x)
34. Lam WW, Hatada I, Ohishi S, Mukai T, Joyce JA, Cole TR, Donnai D, Reik W, Schofield PN & Maher ER 1999 Analysis of germline CDKN1C (p57KIP2) mutations in familial and sporadic Beckwith-Wiedemann syndrome (BWS) provides a novel genotype-phenotype correlation. Journal of Medical Genetics 36 518-523. (doi:10.1136/jmg.36.7.518)
35. Latronico AC, Pinto EM, Domenice S, Fragoso MC, Martin RM, Zerbini MC, Lucon AM & Mendonca BB 2001 An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism 86 4970-4973. (doi:10.1210/jc.86.10.4970)
36. Lau SK & Weiss LM 2009 The Weiss system for evaluating adrenocortical neoplasms: 25 years later. Human Pathology 40 757-768. (doi:10.1016/j.humpath. 2009.03.010)
37. Laurell C, Velazquez-Fernandez D, Lindsten K, Juhlin C, Enberg U, Geli J, Hoog A, Kjellman M, Lundeberg J, Hamberger B et al. 2009 Transcriptional profiling enables molecular classification of adrenocortical tumours. European Journal of Endocrinology 161 141-152. (doi:10.1530/EJE-09-0068)
38. Laurent-Puig P, Legoix P, Bluteau O, Belghiti J, Franco D, Binot F, Monges G, Thomas G, Bioulac-Sage P & Zucman-Rossi J 2001 Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 120 1763-1773. (doi:10.1053/gast.2001. 24798)
39. Lefrancois-Martinez AM, Bertherat J, Val P, Tournaire C, Gallo-Payet N, Hyndman D, Veyssiere G, Bertagna X, Jean C & Martinez A 2004 Decreased expression of cyclic adenosine monophosphate-regulated aldose reductase (AKR1B1) is associated with malignancy in human sporadic adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism 89 3010-3019. (doi:10.1210/jc.2003- 031830)
40. Libe R, Fratticci A & Bertherat J 2007a Adrenocortical cancer: pathophysiology and clinical management. Endocrine-Related Cancer 14 13-28. (doi:10.1677/erc.1.01130)
41. Libe R, Groussin L, Tissier F, Elie C, Rene-Corail F, Fratticci A, Jullian E, Beck-Peccoz P, Bertagna X, Gicquel C et al. 2007b Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity. Clinical Cancer Research 13 844-850. (doi:10.1158/1078-0432.CCR-06-2085)
42. Logie A, Boulle N, Gaston V, Perin L, Boudou P, Le Bouc Y & Gicquel C 1999 Autocrine role of IGF-II in proliferation of human adrenocortical carcinoma NCI H295R cell line. Journal of Molecular Endocrinology 23 23-32. (doi:10.1677/jme.0.0230023)
43. Luton JP, Cerdas S, Billaud L, Thomas G, Guilhaume B, Bertagna X, Laudat MH, Louvel A, Chapuis Y, Blondeau P et al. 1990 Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. New England Journal of Medicine 322 1195-1201. (doi:10.1056/ NEJM199004263221705)
44. Ogawa O, Eccles MR, Szeto J, McNoe LA, Yun K, Maw MA, Smith PJ & Reeve AE 1993 Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour. Nature 362 749-751. (doi:10.1038/362749a0)
45. Ohgaki H, Kleihues P & Heitz PU 1993 p53 mutations in sporadic adrenocortical tumors. International Journal of Cancer 54 408-410. (doi:10.1002/ijc.2910540310)
46. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T et al. 2004 A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New England Journal of Medicine 351 2817-2826. (doi:10.1056/NEJMoa041588)
47. Pollack JR 2007 A perspective on DNA microarrays in pathology research and practice. American Journal of Pathology 171 375-385. (doi:10.2353/ajpath. 2007.070342)
48. Potti A, Mukherjee S, Petersen R, Dressman HK, Bild A, Koontz J, Kratzke R, Watson MA, Kelley M, Ginsburg GS et al. 2006 A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. New England Journal of Medicine 355 570-580. (doi:10.1056/NEJMoa060467)
49. Ragazzon B, Libe R, Gaujoux S, Assie G, Fratticci A, Launay P, Clauser E, Bertagna X, Tissier F, de Reynies A et al. 2010 Transcriptome analysis reveals that p53 and β-catenin alterations occur in a group of aggressive adrenocortical cancers. Cancer Research 70 8276-8281. (doi:10.1158/0008-5472. CAN-10-2014)
50. Rainier S, Johnson LA, Dobry CJ, Ping AJ, Grundy PE & Feinberg AP 1993 Relaxation of imprinted genes in human cancer. Nature 362 747-749. (doi:10.1038/362747a0)
51. Reincke M, Karl M, Travis WH, Mastorakos G, Allolio B, Linehan HM & Chrousos GP 1994 p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. Journal of Clinical Endocrinology and Metabolism 78 790-794. (doi:10.1210/jc.78.3.790)
52. Reincke M, Mora P, Beuschlein F, Arlt W, Chrousos GP & Allolio B 1997 Deletion of the adrenocorticotropin receptor gene in human adrenocortical tumors: implications for tumorigenesis. Journal of Clinical Endocrinology and Metabolism 82 3054-3058. (doi:10.1210/jc.82.9.3054)
53. Reincke M, Beuschlein F, Lalli E, Arlt W, Vay S, Sassone-Corsi P & Allolio B 1998 DAX-1 expression in human adrenocortical neoplasms: implications for steroidogenesis. Journal of Clinical Endocrinology and Metabolism 83 2597-2600. (doi:10.1210/jc.83.7.2597)
54. de Reynies A, Assie G, Rickman DS, Tissier F, Groussin L, Rene-Corail F, Dousset B, Bertagna X, Clauser E & Bertherat J 2009 Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. Journal of Clinical Oncology 27 1108-1115. (doi:10.1200/JCO.2008.18.5678)
55. Ribeiro RC, Sandrini F, Figueiredo B, Zambetti GP, Michalkiewicz E, Lafferty AR, DeLacerda L, Rabin M, Cadwell C, Sampaio G et al. 2001 An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. PNAS 98 9330-9335. (doi:10.1073/pnas.161479898)
56. Rosenberg D, Groussin L, Jullian E, Perlemoine K, Medjane S, Louvel A, Bertagna X & Bertherat J 2003 Transcription factor 3′,5′-cyclic adenosine 5′-monophosphate-responsive element-binding protein (CREB) is decreased during human adrenal cortex tumorigenesis and fetal development. Journal of Clinical Endocrinology and Metabolism 88 3958-3965. (doi:10.1210/jc.2003-030070)
57. Shimizu M, Takai K & Moriwaki H 2009 Strategy and mechanism for the prevention of hepatocellular carcinoma: phosphorylated retinoid X receptor alpha is a critical target for hepatocellular carcinoma chemoprevention. Cancer Science 100 369-374. (doi:10.1111/j.1349-7006.2008.01045.x)
58. Slater EP, Diehl SM, Langer P, Samans B, Ramaswamy A, Zielke A & Bartsch DK 2006 Analysis by cDNA microarrays of gene expression patterns of human adrenocortical tumors. European Journal of Endocrinology 154 587-598. (doi:10.1530/eje.1.02116)
59. Soon PS, Gill AJ, Benn DE, Clarkson A, Robinson BG, McDonald KL & Sidhu SB 2009 Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas. Endocrine-Related Cancer 16 573-583. (doi:10.1677/ERC-08-0237)
60. Szabo PM, Tamasi V, Molnar V, Andrasfalvy M, Tombol Z, Farkas R, Kovesdi K, Patocs A, Toth M, Szalai C et al. 2010 Meta-analysis of adrenocortical tumour genomics data: novel pathogenic pathways revealed. Oncogene 29 3163-3172. (doi:10.1038/onc.2010.80)
61. Tissier F, Cavard C, Groussin L, Perlemoine K, Fumey G, Hagnere AM, Rene-Corail F, Jullian E, Gicquel C, Bertagna X et al. 2005 Mutations of β-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Research 65 7622-7627. (doi:10.1158/0008-5472.CAN-05-0593)
62. Tombol Z, Szabo PM, Molnar V, Wiener Z, Tolgyesi G, Horanyi J, Riesz P, Reismann P, Patocs A, Liko I et al. 2009 Integrative molecular bioinformatics study of human adrenocortical tumors: microRNA, tissue-specific target prediction, and pathway analysis. Endocrine-Related Cancer 16 895-906. (doi:10.1677/ERC-09-0096)
63. Varley JM, McGown G, Thorncroft M, James LA, Margison GP, Forster G, Evans DG, Harris M, Kelsey AM & Birch JM 1999 Are there low-penetrance TP53 alleles? Evidence from childhood adrenocortical tumors American Journal of Human Genetics 65 995-1006. (doi:10.1086/302575)
64. Velazquez-Fernandez D, Laurell C, Geli J, Hoog A, Odeberg J, Kjellman M, Lundeberg J, Hamberger B, Nilsson P & Backdahl M 2005 Expression profiling of adrenocortical neoplasms suggests a molecular signature of malignancy. Surgery 138 1087-1094. (doi:10.1016/j.surg.2005.09.031)
65. Wagner J, Portwine C, Rabin K, Leclerc JM, Narod SA & Malkin D 1994 High frequency of germline p53 mutations in childhood adrenocortical cancer. Journal of the National Cancer Institute 86 1707-1710. (doi:10.1093/jnci/86.22. 1707)
66. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J et al. 2005 Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365 671-679. (doi:10.1016/S0140-6736(05)17947-1)
67. West AN, Neale GA, Pounds S, Figueredo BC, Rodriguez C, Pianovski MA, Oliveira Filho D, Malkin D, Lalli E, Ribeiro R et al. 2007 Gene expression profiling of childhood adrenocortical tumors. Cancer Research 67 600-608. (doi:10.1158/0008-5472.CAN-06-3767)
68. Yano T, Linehan M, Anglard P, Lerman MI, Daniel LN, Stein CA, Robertson CN, LaRocca R & Zbar B 1989 Genetic changes in human adrenocortical carcinomas. Journal of the National Cancer Institute 81 518-523. (doi:10.1093/jnci/81.7.518)